Novo Nordisk’s Sogroya wins EU panel backing for idiopathic short stature
AI Summary- CHMP recommended Sogroya for children with idiopathic short stature and persistent growth problems.
- REAL8 showed comparable annualized height growth after 52 weeks versus daily growth hormone therapy.
- European Commission is expected to decide on three proposed indications later in 2026.